Kemia believes that KC706 may hold the potential to treat conditions such as rheumatoid arthritis, psoriasis, asthma, chronic obstructive pulmonary disorder, and certain metabolic and cardiovascular diseases.
A total of 79 healthy volunteers have received KC706 to date and initial studies have shown that the drug was well tolerated. One assay conducted as part of the phase I trials confirmed that KC706 provided a long-acting, dose-dependent anti-inflammatory effect.
The first phase IIa clinical trial, treating patients suffering from rheumatoid arthritis, will commence at the end of September.
Lew Shuster, Kemia’s CEO stated, “We are pleased with the clinical profile that is emerging for KC706. We will be aggressively pursuing its continued clinical development.”